Clinical Trials
41 trialsAtorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
National Institutes of Health Clinical Center (CC)
Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)
University of Arizona
New Approach to Objectively Measure Social Engagement in Older Adults With Hearing Loss
University of Southern California
Assessment of Patient Experience With Auto-Captioning Glasses in NF2-Related-Schwannomatosis
Massachusetts General Hospital
Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors
City of Hope Medical Center
HEAR
University of Bern
Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma
Akouos, Inc.
Long Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy
Akouos, Inc.
Head and Neck Cancer Survivorship Ototoxicity Screening (SOS)
Washington University School of Medicine
Patients At Risk for Sensory Screening (HPARSS) to Enhance Sensory Deficit Screening in Childhood Cancer Survivors
Washington University School of Medicine
OTOPLAT
Assistance Publique - Hôpitaux de Paris
NIDCD Otolaryngology Clinical Protocol Biospecimen Bank
National Institutes of Health Clinical Center (CC)
Auditory Brainstem Implant (ABI) in Children With No Cochleae or Auditory Nerves
NYU Langone Health
HSA50+
University Hospital Hradec Kralove
CaSPiN
Turku University Hospital
Cisplatin-induced Cochlear and Vestibular Damage in Head and Neck Cancer
Paracelsus Medical University
Radiosurgery Induced Ototoxicity in Patients Treated for a Vestibular Schwannoma
University Hospital, Geneva
Cochlear Implantation After Gamma Knife Radiosurgery with EABR and Correlation to Postoperative Hearing Results - a Pilot Study
Medical University of Vienna
Intraoperative EABR for Decision Making
Medical University of Vienna
SSNHL in Head & Neck Cancer Patients
Nova Scotia Health Authority
EARAD
University of Manchester
MRI-based Synthetic CT Images of the Head and Neck
Amsterdam UMC, location VUmc
Intratympanic N-Acetylcysteine for Prevention of Cisplatin-induced Ototoxicity.
Sunnybrook Health Sciences Centre
AURACCO
Assistance Publique - Hôpitaux de Paris
Study to Evaluate Safety and Efficacy of DB-020 to Protect Hearing in Patients Receiving Cisplatin for Cancer Treatment
Decibel Therapeutics
NAC to Prevent Cisplatin-induced Hearing Loss
Children's Hospital Los Angeles
BioFabry
CENTOGENE GmbH Rostock
Multicenter, Prospective Observational Study for Early Diagnosis, and Development of Follow-up Protocol and Hearing Rehabilitation Program for Ototoxic Hearing Loss After Chemotherapy for Pediatric Solid Cancer
Seoul National University Hospital
Treatment and Prevention of Middle Ear Morbidity in Head and Neck Cancer Patients Following Radiotherapy
Zealand University Hospital
A Compassionate Use Program to Provide Access to Sodium Thiosulfate
TRPHARM
Providing Speech Therapy Awareness in Private Schools
Riphah International University
ABI
Massachusetts Eye and Ear Infirmary
Auditory Brainstem Implant (ABI) in Adult Non-Neurofibromatosis Type 2 Subjects
Massachusetts Eye and Ear Infirmary
UHEAR
General Hospital Groeninge
SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss
Sound Pharmaceuticals, Incorporated
NCGENES
University of North Carolina, Chapel Hill
Study to Evaluate the Safety and Pharmacokinetics of SPI-1005
Sound Pharmaceuticals, Incorporated
Protection From Cisplatin Ototoxicity by Lactated Ringers
University of Oklahoma
Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2
FDA Office of Orphan Products Development
RISGIM
Brigham and Women's Hospital
Hearing Loss and Complaint in Patients With Head and Neck Cancer Treated With Radiotherapy
Hospital A.C. Camargo